[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588943":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":44,"locations":50,"responsibleParty":67,"collaborators":11,"id":69,"slug":11,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":11,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,14,19,22,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","PLACEBO_COMPARATOR",null,[13],"Drug: Placebo Comparator",{"label":15,"type":16,"description":11,"interventionNames":17},"Group 2","EXPERIMENTAL",[18],"Biological: CM512",{"label":20,"type":16,"description":11,"interventionNames":21},"Group 3",[18],{"label":23,"type":16,"description":11,"interventionNames":24},"Group 4",[18],{"label":26,"type":10,"description":11,"interventionNames":27},"Group 5",[13],[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","Placebo Comparator","Placebo subcutaneous injection",[9,26],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"BIOLOGICAL","CM512","CM512 subcutaneous injection",[15,20,23],[40],{"name":41,"affiliation":42,"role":43},"Jianzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Qian Jia","CONTACT","+86-028-88610620","qianjia@keymedbio.com",[51],{"facility":52,"status":53,"city":54,"state":11,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Peking University People's hospital","RECRUITING","Beijing","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64],{"name":41,"role":47,"phone":65,"phoneExt":11,"email":66},"15545433012","rmzjz@126.com",{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588943",false,"NCT06947980","Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria:\n* EASI≥16 at Screening and Baseline visits;\n* Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;\n\n  * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;\n* Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Concurrent disease\u002Fstatus which may potentially affect the efficacy\u002Fsafety judgement.\n* Organ dysfunction.\n* Pregnancy.\n* Other.","ALL","18 Years","75 Years",{"count":79,"type":80},200,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).",[86],"Atopic Dermatitis","2025-08-12",{"date":89,"type":90},"2025-08-17","ACTUAL",{"date":92,"type":90},"2025-06-19",{"date":94,"type":80},"2026-11-07",{"name":5,"class":6},1]